SAT0276 Improvements in Productivity at Paid Work and Within Household, and Increased Participation in Daily Activities After 24 Weeks of Certolizumab Pegol in Patients with Psoriatic Arthritis: Results of Rapid-PSA Study
Authors: A. Kavanaugh, D. Gladman, D. van der Heijde, O. Purcaru, P. J. Mease
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Psoriatic arthritis (PsA) is associated with severe work disability and loss of productivity.<sup>1</sup> The efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in PsA has been reported in RAPID-PsA (NCT01087788).<sup>2</sup> <h3>Objectives</h3> To report the effect of CZP on productivity of paid and household work, and daily activities, in PsA. <h3>Methods</h3> The ongoing 158-week (wk) Phase 3 RAPID-PsA trial is double-blind and placebo (PBO)-controlled to Wk24.<sup>2</sup> Recruited pts had active PsA, had failed ≥1 DMARD, and could have experienced secondary failure to 1 prior anti-TNF. Pts were randomized 1:1:1 to PBO every 2 wks (Q2W), or CZP 400mg at Wk0, 2 and 4 (loading dose) followed by either 200mg CZP Q2W or 400mg CZP every 4 wks (Q4W). Primary efficacy endpoints were ACR20 response at Wk12 and change from baseline (BL) to Wk24 in the van der Heijde modified Total Sharp Score (mTSS). The arthritis-specific Work Productivity Survey (WPS, administered Q4W) was used to assess the impact of PsA on productivity at work, at home and daily activities during the preceding month. WPS responses (LOCF imputation) were compared between treatment arms of the randomized population (RS) using a non-parametric bootstrap-t method. <h3>Results</h3> 409 pts were randomized. 56.6%, 60.1%, and 61.5% of pts in the PBO, CZP 200mg Q2W, and CZP 400mg Q4W treatment arms were employed at study BL; 13%–16% of pts were unable to work due to PsA; 13%–14% were retired. Treatment groups were comparable at BL in terms of workplace and household productivity. At BL, PsA had an impact on absenteeism and presenteeism, and interfered with work productivity; however, the burden of PsA on household productivity and participation in social activities was greater (Table). Compared to PBO, employed pts in both CZP arms reported reduced workplace absenteeism and presenteeism from Wk4 through to Wk24 (Table). CZP arms also reported greater reductions vs PBO in days lost of household work and of family/social/leisure activities per month, in days with reduced household productivity and in PsA interference with household duties as early as Wk4 through to Wk24 (Table). <h3>Image/graph</h3> <h3>Conclusions</h3> CZP significantly improved work productivity in pts with PsA in the workplace by reducing absenteeism, presenteeism and PsA interference with work. CZP also improved household productivity and increased participation in social and daily activities. <h3>References</h3> Tillett W. Rheumatology 2012;51: 275-283, Mease P. Ann Rheum Dis 2012;71(Suppl3): 150 <h3>Acknowledgements</h3> The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma. <h3>Disclosure of Interest</h3> A. Kavanaugh Grant/research support from: Abbott, Amgen, BMS, Pfizer, Roche, Janssen, UCB Pharma, D. Gladman Grant/research support from: Abbott, BMS, Celgene, Johnson &amp; Johnson, MSD, Novartis, Pfizer, UCB Pharma, Consultant for: Abbott, BMS, Celgene, Johnson &amp; Johnson, MSD, Novartis, Pfizer, UCB Pharma, D. van der Heijde Grant/research support from: AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Daiichi, Eli Lilly, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, Vertex, Consultant for: AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Daiichi, Eli Lilly, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, Vertex, Employee of: Imaging Rheumatology bv, O. Purcaru Employee of: UCB Pharma, P. Mease Grant/research support from: Abbott, Amgen, BiogenIdec, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Consultant for: Abbott, Amgen, BiogenIdec, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Speakers bureau: Abbott, Amgen, BiogenIdec, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, UCB Pharma